ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the in vitro and in vivo function of anti-human bladder tumor human-mouse chimeric antibody ch-BDI and its future clinical application.</p><p><b>METHODS</b>With ch-BDI in high-expression cell-line medium, affinity chromatography was used for the purification. Labeled with (99m)Tc through reduction method, its immunoreactive fraction and association constant were measured. The constant was injected into nude mice with xenografted human bladder tumor. The biodistribution of the labeled ch-BDI was studied with radioimmunoimaging.</p><p><b>RESULTS</b>ch-BDI showed desirable immunoreactive fraction (76%) and association constant (3.56 x 10(9) M(-1)) in vitro and a terrific specific targeting effect in vivo.</p><p><b>CONCLUSION</b>ch-BDI has fairly good function against human bladder tumor both in vitro and in vivo, and is promising in clinical use.</p>